Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bmy-14802 SCHEMBL8457738 | 1.00 | SIGMAR1 (1.00) | SIGMAR1DRD2KDM4ECYP1A2GAA | |
| Bmy-14802 SCHEMBL466842 | 0.99 | SIGMAR1 (0.97) | SIGMAR1DRD2KDM4ECYP1A2GAA | |
| Bmy-14802 SCHEMBL10843594 | 0.99 | SIGMAR1 (0.97) | SIGMAR1DRD2KDM4ECYP1A2GAA | |
| SCHEMBL13532643 | 0.93 | SIGMAR1 (0.86) | SIGMAR1DRD2KDM4ECYP1A2GAA | |
| SCHEMBL13532647 | 0.91 | SIGMAR1 (0.84) | SIGMAR1DRD2KDM4ECYP1A2GAA | |
| SCHEMBL13532649 | 0.91 | SIGMAR1 (0.84) | SIGMAR1DRD2KDM4ECYP1A2GAA | |
| SCHEMBL13532633 | 0.91 | SIGMAR1 (0.84) | SIGMAR1DRD2KDM4ECYP1A2GAA | |
| SCHEMBL9602967 | 0.88 | SIGMAR1 (0.79) | SIGMAR1DRD2KDM4ECYP1A2GAA | |
| SCHEMBL13532632 | 0.86 | DRD2 (0.76) | SIGMAR1DRD2KDM4ECYP1A2GAA | |
| SCHEMBL5905729 | 0.83 | SIGMAR1 (0.71) | SIGMAR1DRD2KDM4ECYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025233557-A1 | SIGMA-1 RECEPTOR INHIBITING AGENTS FOR TREATING RHEUMATOID ARTHRITIS | UNIVERSIDAD DE GRANADA (ES) | 2025-11-13 | — | — | WO | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | claimed |
| WO-2014144130-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC (US) | 2014-09-18 | — | — | WO | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| WO-2012055814-A1 | COMPOUND INDUCING LBPA ACCUMULATION FOR INHIBITING CELL-TO-CELL TRANSMISSION OF HIV | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2012-05-03 | — | — | WO | claimed |
| US-5055470-A | METHOD OF TREATMENT OF ISCHEMIA IN BRAIN | BRISTOL-MYERS SQUIBB CO. (US) | 1991-10-08 | — | — | US | claimed |
| US-4605655-A | NEUROLEPTIC AGENTS; NO MOVEMENT DISORDER SIDE EFFECTS | BRISTOL-MYERS COMPANY (US) | 1986-08-12 | — | — | US | claimed |
| US-12612371-B2 | Sigma-1 receptor ligands and therapeutic uses thereof | UNIVERSITE DE STRASBOURG (FR) | 2026-04-28 | — | — | US | disclosed |
| WO-2025233557-A1 | SIGMA-1 RECEPTOR INHIBITING AGENTS FOR TREATING RHEUMATOID ARTHRITIS | UNIVERSIDAD DE GRANADA (ES) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025224085-A1 | COMPOUNDS CAPABLE OF ACTING ON S1R AS WELL AS ON SEH AND USES THEREOF | UNIVERSITAT DE BARCELONA (ES) | 2025-10-30 | — | — | WO | disclosed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-4994460-A | Treatment or prevention of disorders resulting from central nervous system anoxia | BRISTOL-MYERS SQUIBB CO. (US) | 1991-02-19 | — | — | US | disclosed |
| EP-0410114-A2 | Use of 4-[4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl]-1-(4-fluorophenyl)-butanol in pharmaceutical compositions for the treatment of ischemia in brain | Bristol-Myers Squibb Company (US) | 1991-01-30 | — | — | EP | disclosed |
| EP-0410114-A2 | Use of 4-[4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl]-1-(4-fluorophenyl)-butanol in pharmaceutical compositions for the treatment of ischemia in brain | Bristol-Myers Squibb Company (US) | 1991-01-30 | — | — | EP | disclosed |
| EP-0400661-A1 | Agents for treatment of brain ischemia | Bristol-Myers Squibb Company (US) | 1990-12-05 | — | — | EP | disclosed |
| US-4605655-A | NEUROLEPTIC AGENTS; NO MOVEMENT DISORDER SIDE EFFECTS | BRISTOL-MYERS COMPANY (US) | 1986-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612371-B2 | Sigma-1 receptor ligands and therapeutic uses thereof | SIGMAR1, OPRL1, OPRM1 | SIGMAR1 1/4885DRD2 144/4885KDM4E 4221/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | SIGMAR1 174/4885DRD2 345/4885KDM4E 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.